Quick Dispatch:
Your foxo4-dri peptide senolytic 2024 study Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your foxo4-dri peptide senolytic 2024 study Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis ships.
Need Help?
Questions about foxo4-dri peptide senolytic 2024 study Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for foxo4-dri peptide senolytic 2024 study Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis in your area.
Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis
25.25
foxo4-dri human clinical trial FOXO4-DRI 10mg Research Peptide
29.49
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
24.18
Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis
29.77
Peptide Inhibitors Targeting FOXO4-p53 Interactions and Inducing Senescent Cancer Cell-specific Apoptosis
28.90
Frontiers
29.78
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
21.92
